E2F1 inhibition mediates cell death of metastatic melanoma - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Cell Death and Disease Year : 2018

E2F1 inhibition mediates cell death of metastatic melanoma


Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need to develop new therapeutical approaches to bypass resistance and achieve more prolonged responses. In this context, we were interested in E2F1, a transcription factor that plays a major role in the control of cell cycle under physiological and pathological conditions. Here we confirmed that E2F1 is highly expressed in melanoma cells. Inhibition of E2F1 activity further increased melanoma cell death and senescence, both in vitro and in vivo. Moreover, blocking E2F1 also induced death of melanoma cells resistant to BRAF inhibitors. In conclusion, our studies suggest that targeting the E2F1 signaling pathway may be therapeutically relevant for melanoma.


Fichier principal
Vignette du fichier
s41419-018-0566-1.pdf (2.83 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-02529927 , version 1 (02-04-2020)



Florian Rouaud, Nedra Hamouda-Tekaya, Michaël Cerezo, Patricia Abbe, Joséphine Zangari, et al.. E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death and Disease, 2018, 9 (5), pp.527. ⟨10.1038/s41419-018-0566-1⟩. ⟨inserm-02529927⟩
116 View
122 Download



Gmail Facebook X LinkedIn More